Loading viewer...
investor_presentation
Format: PDF investor_presentation
Public Financial Performance for the Quarter ended December 31, 2021 Jatin Dalal Chief Financial Officer Wipro Limited
Financial Performance
for the Quarter ended December 31,
Chief Financial Officer
Public © confidential 2
YoY: 28.5%₹ 203.1 Bn
IT Services Revenue | USD
INR MnPublic © confidential 3
Operating Profit growth
YoY: 5.1% ₹35.5 BnIT Services Operating Margin
Operating Profit (Wipro Ltd.)
in INRIT Services Operating Margin
refers to our segment results
INR MnPublic © confidential 4
EPS: 4.2%Net income refers to the profit attributable
to equity share holders of the company
₹ 5.43Net Income | INR
Earnings Per Share | INR
INR Mn INRPublic © confidential 5
1. Customer count in >$100 Mn account moved from 10 to 17,
>$75 Mn moved from 24 to 29 and > $50Mn account moved
from 38 to 47 YoY in Q3’22
2. Order book in ACV terms grew 27% on year -to-date basis
3. Closed 11 large deals resulting in a TCV of over $600 million
4. Closed acquisition of Edgile, and Leanswift Solutions during
5. Net headcount add of 41,363 employees YoY in Q3’22
6. Operating cash flow to Net income for Q3’22 was at 101.3%
7. Declared an interim dividend of ₹1 ($0.0131) per equity/share
1. Fortheconvenience ofthereaders, theamounts
inIndian Rupees inthis release have been
translated into United States Dollars atthe
Preview truncated — download the full document for the complete content.
investor_presentation
11 Pages
investor_presentation
31 Pages
Cancer Genetics
Regeneron Pharmaceuticals Investor Presentation — January 2017
investor_presentationinvestor_presentation
30 Pages
Regeneron Pharmaceuticals, Inc.